Evidence map›Paper›PMID 25395614›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2015

In vivo nanoparticle assessment of pathological endothelium predicts the development of inflow stenosis in murine arteriovenous fistula.

Jie Cui, Chase W Kessinger, Jason R McCarthy, David E Sosnovik, Peter Libby, Ravi I Thadhani, Farouc A Jaffer

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. The rodent models of arteriovenous fistula.Frontiers in cardiovascular medicine · 2024
    Review
  3. Article
  4. Atorvastatin ReducesJournal of the American Society of Nephrology : JASN · 2020
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jie CuiFrom the Cardiovascular Research Center (J.C., C.W.K., D.E.S., F.A.J.), Division of Cardiology (P.L.), Division of Nephrology (J.C., R.I.T.), Center for System Biology (J.R.M.), Martinos Center for Biomedical Imaging (D.E.S.), and Wellman Center for Photomedicine (F.A.J.), Massachusetts General Hospital, Boston.
Chase W KessingerFrom the Cardiovascular Research Center (J.C., C.W.K., D.E.S., F.A.J.), Division of Cardiology (P.L.), Division of Nephrology (J.C., R.I.T.), Center for System Biology (J.R.M.), Martinos Center for Biomedical Imaging (D.E.S.), and Wellman Center for Photomedicine (F.A.J.), Massachusetts General Hospital, Boston.
Jason R McCarthyFrom the Cardiovascular Research Center (J.C., C.W.K., D.E.S., F.A.J.), Division of Cardiology (P.L.), Division of Nephrology (J.C., R.I.T.), Center for System Biology (J.R.M.), Martinos Center for Biomedical Imaging (D.E.S.), and Wellman Center for Photomedicine (F.A.J.), Massachusetts General Hospital, Boston.
David E SosnovikFrom the Cardiovascular Research Center (J.C., C.W.K., D.E.S., F.A.J.), Division of Cardiology (P.L.), Division of Nephrology (J.C., R.I.T.), Center for System Biology (J.R.M.), Martinos Center for Biomedical Imaging (D.E.S.), and Wellman Center for Photomedicine (F.A.J.), Massachusetts General Hospital, Boston.
Peter LibbyFrom the Cardiovascular Research Center (J.C., C.W.K., D.E.S., F.A.J.), Division of Cardiology (P.L.), Division of Nephrology (J.C., R.I.T.), Center for System Biology (J.R.M.), Martinos Center for Biomedical Imaging (D.E.S.), and Wellman Center for Photomedicine (F.A.J.), Massachusetts General Hospital, Boston.
Ravi I ThadhaniFrom the Cardiovascular Research Center (J.C., C.W.K., D.E.S., F.A.J.), Division of Cardiology (P.L.), Division of Nephrology (J.C., R.I.T.), Center for System Biology (J.R.M.), Martinos Center for Biomedical Imaging (D.E.S.), and Wellman Center for Photomedicine (F.A.J.), Massachusetts General Hospital, Boston.
Farouc A JafferFrom the Cardiovascular Research Center (J.C., C.W.K., D.E.S., F.A.J.), Division of Cardiology (P.L.), Division of Nephrology (J.C., R.I.T.), Center for System Biology (J.R.M.), Martinos Center for Biomedical Imaging (D.E.S.), and Wellman Center for Photomedicine (F.A.J.), Massachusetts General Hospital, Boston. fjaffer@mgh.harvard.edu.
Harvard University Press · US

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 1991 to 2026
$35.3M
Transgenic CoreP30DK057521 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FLOREZ, JOSE CARLOS · 2000 to 2019
$31.4M
Molecular Determinants of Arterial Remodeling in AtherogenesisR01HL080472 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LIBBY, PETER · 2005 to 2018
$5.0M
Cardiac MR and CT ResearchT32HL076136 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NEILAN, TOMAS G · 2004 to 2019
$4.9M
Intravascular Fluorescence Molecular Imaging of Inflammation in AtherosclerosisR01HL108229 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI JAFFER, FAROUC AMIN · 2010 to 2014
$2.1M
NIRF-OFDI of Inflammation in Atheroma Progression and Stent ComplicationsR01HL122388 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI JAFFER, FAROUC AMIN · 2015 to 2018
$2.1M
Cardiovascular Imaging in Ischemic Heart DiseaseK24HL113128 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HOFFMANN, UDO · 2012 to 2020
$1.1M
NHLBI NIH HHS HL080472NHLBI NIH HHS K24 HL113128NHLBI NIH HHS R01 HL080472NHLBI NIH HHS R01 HL108229NHLBI NIH HHS R01 HL122388NHLBI NIH HHS T32 HL076136NIDDK NIH HHS P30 DK043351NIDDK NIH HHS P30 DK057521PHS HHS P41 E8015903-02S1
6 · The paper itself

Abstract

objectiveIn vivo assessment of pathological endothelium within arteriovenous fistula (AVF) could provide new insights into inflow stenosis, a common cause of AVF primary failure in end-stage renal disease patients. Here we developed nanoparticle-based imaging strategies to assess pathological endothelium in vivo and elucidate its relationship to neointimal hyperplasia formation in AVF. APPROACH AND

resultsJugular-carotid AVFs were created in C57BL/6 mice (n=38). Pathological endothelium in the AVF was visualized and quantified in vivo using dextranated magnetofluorescent nanoparticles (CLIO-VT680 [cross-linked iron oxide-VivoTag680]). At day 14, CLIO-VT680 was deposited in AVF, but only minimally in sham-operated arteries. Transmission electron microscopy revealed that CLIO-VT680 resided within endothelial cells and in the intimal extracellular space. Endothelial cells of AVF, but not control arteries, expressed vascular cell adhesion molecule-1 and showed augmented endothelial permeability near the anastomosis. Intravital microscopy demonstrated that CLIO-VT680 deposited most intensely near the AVF anastomosis (P<0.0001). The day 14 intravital microscopy CLIO-VT680 signal predicted the subsequent site and magnitude of AVF neointimal hyperplasia at day 42 (r=0.58, P<0.05). CLIO-VT680 deposition in AVF was further visualized by ex vivo MRI.

conclusionsAVF develop a pathological endothelial response that can be assessed in vivo via nanoparticle-enhanced imaging. AVF endothelium is activated and exhibits augmented permeability, offering a targeting mechanism for nanoparticle deposition and retention in pathological endothelium. The in vivo AVF nanoparticle signal identified and predicted subsequent inflow neointimal hyperplasia. This approach could be used to test therapeutic interventions aiming to restore endothelial health and to decrease early AVF failure caused by inflow stenosis.

Indexed as

DextransFluorescent DyesMagnetic Resonance ImagingMagnetite NanoparticlesMicroscopy, FluorescenceAnimalsArteriovenous FistulaBlood Flow VelocityCapillary PermeabilityCarotid ArteriesCell ProliferationConstriction, PathologicDisease Models, AnimalEndothelium, VascularHyperplasiaJugular VeinsDextransFluorescent DyesMagnetite NanoparticlesVascular Cell Adhesion Molecule-1arteriovenous fistulaendotheliumimagingstenosis

Identifiers

PMID25395614
PMCPMC4270948
OpenAlexW2084042055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.